| __timestamp | Alnylam Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 305409000 |
| Thursday, January 1, 2015 | 60610000 | 377080000 |
| Friday, January 1, 2016 | 89354000 | 432829000 |
| Sunday, January 1, 2017 | 199365000 | 496079000 |
| Monday, January 1, 2018 | 382359000 | 557616000 |
| Tuesday, January 1, 2019 | 479005000 | 658498000 |
| Wednesday, January 1, 2020 | 588420000 | 770456000 |
| Friday, January 1, 2021 | 620639000 | 840100000 |
| Saturday, January 1, 2022 | 770658000 | 944700000 |
| Sunday, January 1, 2023 | 795646000 | 1136600000 |
| Monday, January 1, 2024 | 975526000 | 1464300000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry leaders: Vertex Pharmaceuticals Incorporated and Alnylam Pharmaceuticals, Inc., from 2014 to 2023.
Vertex Pharmaceuticals has consistently increased its SG&A expenses, reflecting a strategic investment in growth and market expansion. From 2014 to 2023, Vertex's expenses surged by approximately 270%, peaking at over $1.1 billion in 2023. This trend underscores Vertex's commitment to maintaining its competitive edge in the biotech sector.
Alnylam Pharmaceuticals, while starting with lower SG&A expenses, has shown a remarkable increase of nearly 1,700% over the same period. By 2023, Alnylam's expenses reached close to $796 million, highlighting its aggressive expansion strategy.
Both companies demonstrate the dynamic nature of the biotech industry, where strategic spending is key to innovation and market leadership.
Eli Lilly and Company and Vertex Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited Trends and Insights
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or United Therapeutics Corporation
Vertex Pharmaceuticals Incorporated or Ascendis Pharma A/S: Who Manages SG&A Costs Better?
Vertex Pharmaceuticals Incorporated and Cytokinetics, Incorporated: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Rhythm Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Veracyte, Inc.
Vertex Pharmaceuticals Incorporated vs Wave Life Sciences Ltd.: SG&A Expense Trends
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and MannKind Corporation